LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Síndrome de Noonan: actualización genética, clínica y de opciones terapéuticas.

    Carcavilla, Atilano / Suárez-Ortega, Larisa / Rodríguez Sánchez, Amparo / Gonzalez-Casado, Isabel / Ramón-Krauel, Marta / Labarta, Jose Ignacio / Quinteiro Gonzalez, Sofia / Riaño Galán, Isolina / Ezquieta Zubicaray, Begoña / López-Siguero, Juan Pedro

    Anales de pediatria

    2020  Volume 93, Issue 1, Page(s) 61.e1–61.e14

    Abstract: Noonan syndrome (NS) is a relatively common genetic condition characterised by short stature, congenital heart defects, and distinctive facial features. NS and other clinically overlapping conditions such as NS with multiple lentigines (formerly called ... ...

    Title translation Noonan syndrome: genetic and clinical update and treatment options.
    Abstract Noonan syndrome (NS) is a relatively common genetic condition characterised by short stature, congenital heart defects, and distinctive facial features. NS and other clinically overlapping conditions such as NS with multiple lentigines (formerly called LEOPARD syndrome), cardiofaciocutaneous syndrome, or Costello syndrome, are caused by mutations in genes encoding proteins of the RAS-MAPKinases pathway. Because of this shared mechanism, these conditions have been collectively termed «RASopathies». Despite the recent advances in molecular genetics, nearly 20% of patients still lack a genetic cause, and diagnosis is still made mainly on clinical grounds. NS is a clinically and genetically heterogeneous condition, with variable expressivity and a changing phenotype with age, and affects multiple organs and systems. Therefore, it is essential that physicians involved in the care of these patients are familiarised with their manifestations and the management recommendations, including management of growth and development. Data on growth hormone treatment efficacy are sparse, and show a modest response in height gains, similar to that observed in Turner syndrome. The role of RAS/MAPK hyper-activation in the pathophysiology of this group of disorders offers a unique opportunity for the development of targeted approaches.
    MeSH term(s) Diagnosis, Differential ; Genetic Markers ; Genotype ; Humans ; Mitogen-Activated Protein Kinases/genetics ; Mutation ; Noonan Syndrome/diagnosis ; Noonan Syndrome/genetics ; Noonan Syndrome/physiopathology ; Noonan Syndrome/therapy ; Phenotype ; Proto-Oncogene Proteins p21(ras)/genetics
    Chemical Substances Genetic Markers ; Mitogen-Activated Protein Kinases (EC 2.7.11.24) ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
    Language Spanish
    Publishing date 2020-05-31
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2830901-7
    ISSN 2341-2879 ; 2341-2879
    ISSN (online) 2341-2879
    ISSN 2341-2879
    DOI 10.1016/j.anpedi.2020.04.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: A 7-year follow-up retrospective, international, multicenter study of insulin pump therapy in children and adolescents with type 1 diabetes.

    Mameli, Chiara / Scaramuzza, Andrea E / Ho, Josephine / Cardona-Hernandez, Roque / Suarez-Ortega, Larisa / Zuccotti, Gian Vincenzo

    Acta diabetologica

    2014  Volume 51, Issue 2, Page(s) 205–210

    Abstract: We evaluated the long-term glycemic control in children with type 1 diabetes, using continuous subcutaneous insulin infusion (CSII) for at least 5 years in three diabetes centers from three different countries: Canada, Italy and Spain. This was an ... ...

    Abstract We evaluated the long-term glycemic control in children with type 1 diabetes, using continuous subcutaneous insulin infusion (CSII) for at least 5 years in three diabetes centers from three different countries: Canada, Italy and Spain. This was an observational retrospective multicenter cohort study. Subjects were included if they were followed at one of the participating centers, had type 1 diabetes, age 5-20 years at time of data collection and used CSII for more than 5 years. Data collected included gender, age, disease duration, age at CSII initiation, body mass index (BMI), hemoglobin A1c (HbA1c), insulin requirement and serious adverse events (SAE) at baseline and every 12 months during follow-up. One hundred fifteen patients were included in the study (55% males), aged 5-20 years (mean: 13.5 ± 3.8 years), with mean diabetes duration of 6.3 ± 3.4 years, using CSII for mean of 6.9 ± 1.2 years (range 5-12 years.). HbA1c significantly improved after 1 year of CSII treatment and during follow-up (p = 0.02). When HbA1c was compared between countries, a difference was observed, with slightly lower values in Italy than in Canada and Spain (p = 0.04). When evaluated by gender, HbA1c was similar at baseline, but significantly improved only in males during all follow-up (p = 0.004). No significant differences were observed for BMI, insulin requirement or SAE. Insulin pump therapy is safe and effective in the pediatric population, although in this study, the major benefit in HbA1c was seen in males. The use of advanced pump features was associated with greater improvement in HbA1c.
    MeSH term(s) Adolescent ; Body Mass Index ; Canada ; Child ; Child, Preschool ; Cohort Studies ; Diabetes Mellitus, Type 1/blood ; Diabetes Mellitus, Type 1/drug therapy ; Female ; Follow-Up Studies ; Glycated Hemoglobin A/metabolism ; Humans ; Insulin/administration & dosage ; Insulin/adverse effects ; Insulin Infusion Systems ; Italy ; Male ; Retrospective Studies ; Spain ; Young Adult
    Chemical Substances Glycated Hemoglobin A ; Insulin
    Language English
    Publishing date 2014-04
    Publishing country Germany
    Document type Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 1097676-0
    ISSN 1432-5233 ; 0940-5429
    ISSN (online) 1432-5233
    ISSN 0940-5429
    DOI 10.1007/s00592-013-0481-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Clinical and Molecular Description of 16 Families With Heterozygous IHH Variants.

    Sentchordi-Montané, Lucía / Benito-Sanz, Sara / Aza-Carmona, Miriam / Pereda, Arrate / Parrón-Pajares, Manuel / de la Torre, Carolina / Vasques, Gabriela A / Funari, Mariana F A / Travessa, André M / Dias, Patrícia / Suarez-Ortega, Larisa / González-Buitrago, Jesús / Portillo-Najera, Nancy Elizabeth / Llano-Rivas, Isabel / Martín-Frías, María / Ramírez-Fernández, Joaquín / Sánchez Del Pozo, Jaime / Garzón-Lorenzo, Lucía / Martos-Moreno, Gabriel A /
    Alfaro-Iznaola, Cristina / Mulero-Collantes, Inés / Ruiz-Ocaña, Pablo / Casano-Sancho, Paula / Portela, Ana / Ruiz-Pérez, Lorea / Del Pozo, Angela / Vallespín, Elena / Solís, Mario / Lerario, Antônio M / González-Casado, Isabel / Ros-Pérez, Purificación / Pérez de Nanclares, Guiomar / Jorge, Alexander A L / Heath, Karen E

    The Journal of clinical endocrinology and metabolism

    2020  Volume 105, Issue 8

    Abstract: Context: Heterozygous variants in the Indian hedgehog gene (IHH) have been reported to cause brachydactyly type A1 and mild hand and feet skeletal anomalies with short stature. Genetic screening in individuals with short stature and mild skeletal ... ...

    Abstract Context: Heterozygous variants in the Indian hedgehog gene (IHH) have been reported to cause brachydactyly type A1 and mild hand and feet skeletal anomalies with short stature. Genetic screening in individuals with short stature and mild skeletal anomalies has been increasing over recent years, allowing us to broaden the clinical spectrum of skeletal dysplasias.
    Objective: The objective of this article is to describe the genotype and phenotype of 16 probands with heterozygous variants in IHH.
    Patients and methods: Targeted next-generation sequencing or Sanger sequencing was performed in patients with short stature and/or brachydactyly for which the genetic cause was unknown.
    Results: Fifteen different heterozygous IHH variants were detected, one of which is the first reported complete deletion of IHH. None of the patients showed the classical phenotype of brachydactyly type A1. The most frequently observed clinical characteristics were mild to moderate short stature as well as shortening of the middle phalanx on the fifth finger. The identified IHH variants were demonstrated to cosegregate with the short stature and/or brachydactyly in the 13 probands whose family members were available. However, clinical heterogeneity was observed: Two short-statured probands showed no hand radiological anomalies, whereas another 5 were of normal height but had brachydactyly.
    Conclusions: Short stature and/or mild skeletal hand defects can be caused by IHH variants. Defects in this gene should be considered in individuals with these findings, especially when there is an autosomal dominant pattern of inheritance. Although no genotype-phenotype correlation was observed, cosegregation studies should be performed and where possible functional characterization before concluding that a variant is causative.
    MeSH term(s) Adolescent ; Body Height/genetics ; Brachydactyly/diagnosis ; Brachydactyly/genetics ; Child ; Child, Preschool ; Cohort Studies ; DNA Mutational Analysis ; Female ; Hand/diagnostic imaging ; Hedgehog Proteins/genetics ; Humans ; Infant ; Male ; Mutation ; Pedigree ; Polymorphism, Single Nucleotide ; Radiography
    Chemical Substances Hedgehog Proteins ; IHH protein, human
    Language English
    Publishing date 2020-04-20
    Publishing country United States
    Document type Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 3029-6
    ISSN 1945-7197 ; 0021-972X
    ISSN (online) 1945-7197
    ISSN 0021-972X
    DOI 10.1210/clinem/dgaa218
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top